DAWN - Company ID 0001845337
The table below shows Day One Biopharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$59.00M | -$49.73M | -$25.98M | -$21.56M | -$9.74M |
| Capital expenditure | $317.00K | $0.00 | $26.00K | $15.00K | - |
| Investing cash flow | -$32.61M | $89.29M | -$11.19M | -$15.00K | -$8.00M |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - |
Day One Biopharmaceuticals, Inc. reported operating cash flow of -$103.76M for fiscal year 2025. That is down 32.8% from -$78.11M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$4.51M (FY 2019) to -$103.76M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| - |
| Financing cash flow | $0.00 | $48.00K | $1.18M | $0.00 | $128.88M |